Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPOR | P19235 | 3/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TET2 | Q6N021 | 3/20 | 0.39 |
| ▸ | KDM4A | O75164 | 2/20 | 0.39 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.39 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.39 |
| ▸ | TET3 | O43151 | 1/20 | 0.39 |
| ▸ | FOLH1 | Q04609 | 4/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | GRM8 | O00222 | 1/20 | 0.38 |
| ▸ | GRM6 | O15303 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL226189 | 1.00 | EPOR (0.43) | EPORSLC6A2SLC6A4BLMSLC6A3 | |
| SCHEMBL28959981 | 0.85 | BLM (0.42) | EPORSLC6A2SLC6A4BLMSLC6A3 | |
| SCHEMBL28959979 | 0.85 | BLM (0.42) | EPORSLC6A2SLC6A4BLMSLC6A3 | |
| SCHEMBL27718821 | 0.84 | BLM (0.38) | EPORSLC6A2SLC6A4BLMSLC6A3 | |
| SCHEMBL10355086 | 0.83 | SLC6A2 (0.41) | EPORSLC6A2SLC6A4BLMSLC6A3 | |
| SCHEMBL12669398 | 0.82 | EPOR (0.44) | EPORSLC6A2SLC6A4BLMSLC6A3 | |
| SCHEMBL10714615 | 0.80 | EPOR (0.40) | EPORFOLH1ALDH1A1 | |
| SCHEMBL4461285 | 0.79 | SLC6A2 (0.35) | EPORSLC6A2SLC6A4BLMSLC6A3 | |
| SCHEMBL2557862 | 0.78 | GRIK1 (0.38) | CYP2C19GRIK1GRIK2ALDH1A1ABCC4 | |
| SCHEMBL29817200 | 0.78 | SMPD2 (0.42) | GRIK1GRIK2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210188979-A1 | Therapeutic Nanoparticles Comprising A Therapeutic Agent And Methods of Making and Using Same | PFIZER INC. (US) | 2021-06-24 | — | — | US | disclosed |
| US-20200093827-A1 | Pemetrexed Polymeric Nanoparticles And Methods Of Making And Using Same | PFIZER INC. (US) | 2020-03-26 | — | — | US | disclosed |
| EP-2774608-B1 | Drug loaded polymeric nanoparticles and methods of making and using same | PFIZER (US) | 2019-11-20 | — | — | EP | disclosed |
| EP-3413918-A1 | THERAPEUTIC NANOPARTICLES COMPRISING A THERAPEUTIC AGENT AND METHODS OF MAKING AND USING SAME | Pfizer Inc (US) | 2018-12-19 | — | — | EP | disclosed |
| US-20180256584-A1 | Pemetrexed Polymeric Nanoparticles And Methods Of Making And Using Same | PFIZER INC. (US) | 2018-09-13 | — | — | US | disclosed |
| US-10071056-B2 | Cancer cell targeting using nanoparticles | PFIZER INC. (US) | 2018-09-11 | — | — | US | disclosed |
| US-9872913-B2 | Drug loaded polymeric nanoparticles and methods of making and using same | PFIZER INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-20170266187-A1 | Pemetrexed Polymeric Nanoparticles And Methods Of Making And Using Same | PFIZER INC. (US) | 2017-09-21 | — | — | US | disclosed |
| EP-2644594-B1 | Cancer Cell Targeting Using Nanoparticles | PFIZER (US) | 2017-08-23 | — | — | EP | disclosed |
| WO-2017137953-A1 | THERAPEUTIC NANOPARTICLES COMPRISING A THERAPEUTIC AGENT AND METHODS OF MAKING AND USING SAME | PFIZER INC. (US) | 2017-08-17 | — | — | WO | disclosed |
| EP-1021712-A4 | PHOSPHORESCENT DENDRITIC MACROMOLECULAR COMPOUNDS FOR IMAGING TISSUE OXYGEN | UNIV PENNSYLVANIA (US) | 2000-07-26 | — | — | EP | disclosed |
| EP-0804413-B1 | NITROGEN MUSTARD PRODRUGS WITH NOVEL LIPOPHILIC PROTECTING GROUPS, AND PROCESSES FOR THEIR PRODUCTION | CANCER RES CAMPAIGN TECH (GB) | 2000-05-17 | — | — | EP | disclosed |
| WO-2000026643-A1 | METHOD FOR NON-INVASIVE IMAGING OXYGEN DISTRIBUTION IN MULTI-DIMENSIONS AND APPARATUS THEREFOR | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2000-05-11 | — | — | WO | disclosed |
| EP-0988396-A1 | METHOD FOR RAPID DETECTION OF BACTERIAL GROWTH IN CULTURES | TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2000-03-29 | — | — | EP | disclosed |
| US-6005002-A | Nitrogen mustard prodrugs with novel lipophilic protecting groups, and processes for their production | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1999-12-21 | — | — | US | disclosed |
| WO-1998054354-A1 | METHOD FOR RAPID DETECTION OF BACTERIAL GROWTH IN CULTURES | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 1998-12-03 | — | — | WO | disclosed |
| US-5837865-A | Phosphorescent dendritic macromolecular compounds for imaging tissue oxygen | TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 1998-11-17 | — | — | US | disclosed |
| WO-1998026708-A1 | PHOSPHORESCENT DENDRITIC MACROMOLECULAR COMPOUNDS FOR IMAGING TISSUE OXYGEN | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 1998-06-25 | — | — | WO | disclosed |
| EP-0804413-A1 | NITROGEN MUSTARD PRODRUGS WITH NOVEL LIPOPHILIC PROTECTING GROUPS, AND PROCESSES FOR THEIR PRODUCTION | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1997-11-05 | — | — | EP | disclosed |
| WO-1996022277-A1 | NITROGEN MUSTARD PRODRUGS WITH NOVEL LIPOPHILIC PROTECTING GROUPS, AND PROCESSES FOR THEIR PRODUCTION | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1996-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210188979-A1 | Therapeutic Nanoparticles Comprising A Therapeutic Agent And Methods of Making and Using Same | CD47, CD274, PDCD1 | EPOR 171/4885SLC6A2 4669/4885SLC6A4 4782/4885 |
| US-10071056-B2 | Cancer cell targeting using nanoparticles | CD47, EPCAM, CD44 | EPOR 553/4885SLC6A2 2581/4885SLC6A4 4162/4885 |
| US-20200093827-A1 | Pemetrexed Polymeric Nanoparticles And Methods Of Making And Using Same | MTHFD1, TYMP, FPGS | EPOR 1889/4885SLC6A2 2268/4885SLC6A4 3392/4885 |
| US-20170266187-A1 | Pemetrexed Polymeric Nanoparticles And Methods Of Making And Using Same | MTHFD1, TYMP, FPGS | EPOR 1889/4885SLC6A2 2268/4885SLC6A4 3392/4885 |
| US-20180256584-A1 | Pemetrexed Polymeric Nanoparticles And Methods Of Making And Using Same | MTHFD1, TYMP, FPGS | EPOR 1889/4885SLC6A2 2268/4885SLC6A4 3392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.